Latest dermatology news

Sun Pharmaceutical industries’ (Sun Pharma) supplemental Biologics License Application (sBLA) for ILUMYA (tildrakizumab) to treat adults with active psoriatic arthritis (PsA) has been accepted for review by the US FDA. 

Biogen’s AMETHYST phase 2/3 study (Part A) of litifilimab in people living with cutaneous lupus erythematosus (CLE) has shown positive results. 

Arcutis Biotherapeutics has published data from the phase 3 open-label extension (OLE) study (INTEGUMENT-OLE) evaluating ZORYVE (roflumilast) in children aged two to five years with mild-to-moderate atopic dermatitis. 

The National Institute for Health and Care Excellence (NICE) has released a draft scope of the Health Technology Evaluation (HTA) for the use of povorcitinib as a treatment for moderate-to-severe active hidradenitis suppurativa (HS) after a TNF-alpha inhibitor. 

The American Academy of Dermatology (ADD) has published guidelines of care for the prevention and management of atopic dermatitis in paediatric patients. 

Novartis’ Cosentyx (secukinumab) has received US FDA approval to treat paediatric patients aged 12 years and older with moderate-to-severe hidradenitis suppurativa (HS), making it the only IL-17A inhibitor for this population.

Takeda has released the outcome of two phase 3 studies of zasocitinib (TAK-279) in adults with moderate-to-severe plaque psoriasis (PsO), with data presented at the 2026 American Academy of Dermatology (ADD) Annual Meeting. 

UCB announced new data from the evaluation of BIMZELX (bimekizumab) at the 2026 American Academy of Dermatology (ADD) Annual Meeting in Denver, US. 

A new pre-filled syringe version of Shingrix, GSK’s vaccine for shingles, has received a positive opinion from the European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).

New results from the phase 3 BRAVE-AA-PEDS trial of Lilly’s baricitinib have shown near-complete scalp hair regrowth in adolescents with severe alopecia areata (AA).